Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crescent Biopharma (CBIO) Cash from Financing Activities (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed Cash from Financing Activities for 10 consecutive years, with $178.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Financing Activities changed N/A to $178.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $324.2 million, a N/A change, with the full-year FY2025 number at $323.0 million, up 5983301.26% from a year prior.
  • Cash from Financing Activities was $178.9 million for Q4 2025 at Crescent Biopharma, up from $145.4 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $178.9 million in Q4 2025 to a low of $999.0 in Q4 2023.
  • A 4-year average of $36.4 million and a median of $600617.0 in 2021 define the central range for Cash from Financing Activities.
  • Peak YoY movement for Cash from Financing Activities: soared 7258.46% in 2021, then tumbled 99.98% in 2024.
  • Crescent Biopharma's Cash from Financing Activities stood at $1.1 million in 2021, then tumbled by 99.91% to $999.0 in 2023, then skyrocketed by 390.29% to $4898.0 in 2024, then soared by 3651594.57% to $178.9 million in 2025.
  • Per Business Quant, the three most recent readings for CBIO's Cash from Financing Activities are $178.9 million (Q4 2025), $145.4 million (Q2 2025), and $4898.0 (Q1 2024).